ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA approves Besremi to treat rare blood disease EuropeanPharmaceuticalReview
November 17, 2021The FDA approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. -
FDA Approves Treatment for Rare Blood Disease FDA
November 16, 2021Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells.
Pharma Sources Insight July 2025
